Cargando…
Patient selection for hemophilia gene therapy: Real‐life data from a single center
BACKGROUND: While the number of individuals with hemophilia who are expected to be or have already been included in gene therapy trials has been regularly reported, the number of unscreened or excluded individuals, in addition to the reasons for exclusion, is mostly not reported. METHODS: We conduct...
Autores principales: | Krumb, Evelien, Lambert, Catherine, Hermans, Cedric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8035793/ https://www.ncbi.nlm.nih.gov/pubmed/33870024 http://dx.doi.org/10.1002/rth2.12494 |
Ejemplares similares
-
Living with a “hemophilia‐free mind” – The new ambition of hemophilia care?
por: Krumb, Evelien, et al.
Publicado: (2021) -
The bleeding phenotype in people with nonsevere hemophilia
por: Kloosterman, Fabienne R., et al.
Publicado: (2022) -
Hemophilia gene therapy knowledge and perceptions: Results of an international survey
por: Peyvandi, Flora, et al.
Publicado: (2020) -
Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors
por: Schweiger, Helmut, et al.
Publicado: (2022) -
Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication
por: Paul, Helmut, et al.
Publicado: (2022)